Cadian Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Cadian Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-550,000	Closed	-$71M	–	31
2019 Q4	$71M	Sell	550,000 -702,500	-56%	-$70.9M	3.14%	14
2019 Q3	$94.3M	Buy	1,252,500 +704,000	+128%	+$83.1M	4.48%	11
2019 Q2	$83.3M	Sell	548,500 -62,046	-10%	-$7.54M	3.76%	11
2019 Q1	$72.8M	Buy	610,546 +329,000	+117%	+$42.3M	2.84%	15
2018 Q4	$30.7M	Sell	281,546 -106,054	-27%	-$13.3M	1.43%	21
2018 Q3	$62.6M	Buy	387,600 +107,600	+38%	+$14.7M	2.84%	14
2018 Q2	$37M	Buy	+280,000	New	+$26.4M	1.78%	19
2017 Q3	–	Sell	-621,458	Closed	-$20.9M	–	48
2017 Q2	$20.9M	Buy	621,458 +275,647	+80%	+$8.98M	1.02%	29
2017 Q1	$10.2M	Sell	345,811 -3,143	-0.9%	-$97.3K	0.49%	35
2016 Q4	$9.57M	Buy	+348,954	New	+$14M	0.51%	34

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cadian Capital Management's SRPT Position: Q1 2020 in Review

Cadian Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 550,000 shares — an estimated $71M sold.

Cadian Capital Management first reported a position in SRPT in Q4 2016 and held it in 10 quarters. The position peaked at $94.3M in Q3 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

Cadian Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
Cadian Capital Management sold 550,000 Sarepta Therapeutics shares in Q1 2020, an estimated $71M.
Cadian Capital Management first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 10 quarters.
Cadian Capital Management's Sarepta Therapeutics position peaked at $94.3M in Q3 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Cadian Capital Management's 13F filing for Q1 2020, filed 14 May 2020.